These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26016605)

  • 1. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
    Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H
    Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration.
    Rezar-Dreindl S; Sacu S; Eibenberger K; Pollreisz A; Bühl W; Georgopoulos M; Krall C; Weigert G; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4144-50. PubMed ID: 27537264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
    Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
    Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenin, FGF-α, and IL-36β have higher expression levels in aqueous humor of nAMD patients in comparison to cataract patients.
    Chen K; Xu W; Zheng J; Shen Y; Ma J; Chen Z
    BMC Ophthalmol; 2020 Oct; 20(1):431. PubMed ID: 33115414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
    Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization.
    Sun T; Wei Q; Gao P; Zhang Y; Peng Q
    Drug Des Devel Ther; 2021; 15():2457-2467. PubMed ID: 34140764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
    Enders P; Muether PS; Hermann M; Ristau T; Fauser S
    Retina; 2015 Mar; 35(3):454-8. PubMed ID: 25170863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S; Muether PS
    Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
    Hata M; Yamashiro K; Ooto S; Oishi A; Tamura H; Miyata M; Ueda-Arakawa N; Takahashi A; Tsujikawa A; Yoshimura N
    Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):292-298. PubMed ID: 28114590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration.
    Motohashi R; Noma H; Yasuda K; Kotake O; Goto H; Shimura M
    Ophthalmic Res; 2017; 58(4):209-216. PubMed ID: 28796997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
    Saunders DJ; Muether PS; Fauser S
    Br J Ophthalmol; 2015 Nov; 99(11):1554-9. PubMed ID: 25957377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
    Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
    Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
    Front Immunol; 2021; 12():738521. PubMed ID: 34721402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration.
    Uzun A; Yalcindag FN; Demirel S; Batýoðlu F; Ozmert E
    Ocul Immunol Inflamm; 2017 Apr; 25(2):229-232. PubMed ID: 26828124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.